Surrogate markers of cardiovascular disease in nondiabetic chronic kidney disease: Mean platelet volume and B-thromboglobulin
Acta Medica Mediterranea, cilt.30, sa.4, ss.929-933, 2014 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 30 Sayı: 4
- Basım Tarihi: 2014
- Dergi Adı: Acta Medica Mediterranea
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.929-933
- Anahtar Kelimeler: Nondiabetic chronic renal disease, mean platelet volume, beta-thromboglobulin, cardiovascular risk, hemodialysis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aims: To investigate the levels of mean platelet volume (MPV) and beta-thromboglobulin (β-TG), two of platelet activation markers, in non-diabetic patients in different stages of chronic kidney disease (CKD), who were receiving or not receiving hemodialysis. Material and methods: This prospective study included 122 subjects (88 CKD patients and 34 healthy controls). Analyses were performed among three groups: dialysis group including patients (n=50) with nondiabetic stage 5 CKD and receiving hemodialysis, non-dialysis group including patients (n=38) with nephropathy of nondiabetic stage 1-4 CKD and not receiving hemodialysis, and healthy controls (n=34). Demographic data, medical history, and cardiac risk factors were recorded. Physical examinations and measurements of complete blood count, and MPV and β-TG levels were performed. Plasma β-TG levels were determined by the enzyme- linked immunosorbent assay method. Results: The mean age of the study subjects (n=122; 78 females) were 54.56±17.20 years. Hypertension (38.6%) and polycystic kidney disease (13.6%) were the major etiologies of CKD. The β-TG level of the non-dialysis group was significantly higher than those of the dialysis (p=0.001) and control groups (p<0.01). The MPV levels of the non-dialysis and dialysis groups were significantly higher than that of the control group (p=0.001and p=0.011, respectively). Conclusion: Both MPV and β-TG levels were higher in the non-dialysis CKD patients than in the control group. Monitoring of these two markers (MPV and β-TG) in early-stage CKD patients would be beneficial as these markers may be useful in early detection of the cardiovascular risks and as their measurements are non-invasive and easily applicable.